Alexei A Grom MD
Associate Professor, Pediatrics, University of Cincinnati College of Medicine
Join to view full profile
3333 Burnet AveMl 4010Cincinnati, OH 45229
Phone+1 513-636-7686
Fax+1 513-636-5568
Dr. Grom is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1997 - 1998
St Petersburg Medical State AcademyClass of 1986
Certifications & Licensure
KY State Medical License 2021 - 2027
OH State Medical License 1999 - 2027
IN State Medical License 2021 - 2023
American Board of Pediatrics Pediatric Rheumatology
Awards, Honors, & Recognition
- Fellow American College of Rheumatology
Publications & Presentations
PubMed
- Dr. Eloseily et al reply.Esraa Eloseily, Joy Elizabeth Baker, Grant Schulert, Alexei Grom
The Journal of Rheumatology. 2026-10-01 - Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.Francesco Baldo, Greta Rogani, Remco G A Erkens, Mao Mizuta, Claudia Bracaglia
Arthritis & Rheumatology. 2026-09-21 - AMETHYST: a Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-refractory Macrophage Activation Syndrome Complicating Still'...Alexei Grom, Jordi Antón, Edward M Behrens, Corey Best, Norbert Blank
Arthritis & Rheumatology. 2026-09-07
Other
- Juvenile idiopathic arthritis: Epidemiology and immunopathogenesisGrom AA
http://www.uptodate.com/contents/juvenile-idiopathic-arthritis-epidemiology-and-immunopathogenesis
UpToDate, Wolters Kluwer Health - 2012-10-31
Press Mentions
Sobi Showcases New Data Across Rare Inflammatory Conditions at ACR 2025October 24th, 2025
FDA Approves First Treatment for Macrophage Activation Syndrome in Still DiseaseJune 30th, 2025
FDA Approves Gamifant (Emapalumab-Lzsg) as First-Ever Treatment for Adults and Children with Macrophage Activation Syndrome in Still's DiseaseJune 28th, 2025
Grant Support
- Cincinnati Training Program in Pediatric RheumatologyCINCINNATI CHILDRENS HOSP MED CTR2016–2030
- Cincinnati Training Program in Pediatric RheumatologyCINCINNATI CHILDRENS HOSP MED CTR2016–2030
- Pathobiology Of The Monomyelocytoid Cell Gene Expression Signature In SystemicjiaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
- MUNC13-4 Gene Polymorphisms In Macrophage Activation Syndrome And Systemic JuveniNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
- Macrophage Activation Syndrome Biomarkers In Systemic Juvenile Idiopathic ARTNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: